Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009046984 - HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES

Publication Number WO/2009/046984
Publication Date 16.04.2009
International Application No. PCT/EP2008/008544
International Filing Date 09.10.2008
Chapter 2 Demand Filed 01.07.2009
IPC
C12N 15/10 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
A61K 39/21 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
CPC
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
C12N 2740/16134
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
16011Human Immunodeficiency Virus, HIV
16111concerning HIV env
16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • TECHNOLOGIE INTEGRALE LTD. [AT]/[AT] (AllExceptUS)
  • FILINOVA, Elena, Yu. [RU]/[RU] (UsOnly)
Inventors
  • FILINOVA, Elena, Yu.
Agents
  • BECKER KURIG STRAUS
Priority Data
60/978,53609.10.2007US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES
(FR) VACCIN PRÉVENTIF CONTRE VIH À BASE D'ANTICORPS SPÉCIFIQUE DE VIH
Abstract
(EN)
The present invention relates to a method for producing a HIV vaccine, preventing infection with HIV and/or preventing the development of HIV infection in an individual. In particular, the present invention provides formation of HIV specific antibodies capable to recognize and bind to substantially all HIV-isoforms as an immune response in an individual, which bind to existing in a current epidemiologic cohort HIV-subtypes and mutants selected after antiretroviral therapy. The present invention also relates to HIV-1 peptides/polypeptides/proteins selection with reverse panning technique, LC mass spectrometry identification of HIV-1 env peptides/polypeptides/proteins, gp120 and its fragment in particular, production of recombinant HIV-1 env peptides in suitable host with necessary glycosylation - L. tarentolae and using sterically stabilized liposomes (SSL) as an adjuvant-carrier for HIV-specific immune boost composition.
(FR)
La présente invention concerne un procédé de production d'un vaccin contre le VIH, de prévention d'une infection à VIH et/ou de prévention du développement d'une infection à VIH chez un individu. En particulier, la présente invention concerne la formation d'anticorps spécifiques de VIH capables de reconnaître et de se lier substantiellement à toutes les isoformes de VIH en tant que réponse immunitaire chez un individu, qui se lient à des sous-types de VIH existants dans une cohorte épidémiologique actuelle et des mutants choisis après un traitement antirétroviral. La présente invention concerne également la sélection de peptides/polypeptides/protéines de VIH-1 par une technique d'adhérence inverse, identification par spectrométrie de masse LC de peptides/polypeptides/protéines de VIH-1 env, gp120 et leur fragment, en particulier, la production de peptides de VIH-1 env recombinants chez un hôte approprié avec une glycosylation nécessaire - L. tarentolae et en utilisant des liposomes stériquement stabilisés (SSL) comme adjuvant-véhicule pour la composition de stimulation immunitaire spécifique de VIH.
Latest bibliographic data on file with the International Bureau